Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622631 | 0.86 | SRC (0.44) | SIRT1SRCMTNR1BMTNR1AALDH1A1 | |
| SCHEMBL6243498 | 0.86 | MTNR1A (0.43) | SRCMTNR1BMTNR1AALDH1A1HTR5A | |
| SCHEMBL6137895 | 0.84 | CASP1 (0.43) | SRCMTNR1BMTNR1AALDH1A1DRD2 | |
| SCHEMBL6197384 | 0.84 | ALOX15 (0.42) | MTNR1BMTNR1AALDH1A1HPGDHSD17B10 | |
| SCHEMBL6200356 | 0.84 | CASP1 (0.43) | SRCMTNR1BMTNR1AALDH1A1DRD2 | |
| SCHEMBL6200359 | 0.84 | CASP1 (0.43) | SRCMTNR1BMTNR1AALDH1A1DRD2 | |
| SCHEMBL6197387 | 0.84 | ALOX15 (0.42) | MTNR1BMTNR1AALDH1A1HPGDHSD17B10 | |
| SCHEMBL6197391 | 0.84 | ALOX15 (0.42) | MTNR1BMTNR1AALDH1A1HPGDHSD17B10 | |
| SCHEMBL7430923 | 0.80 | ALDH1A1 (0.49) | SRCALDH1A1SMN1; SMN2DRD2DRD3 | |
| SCHEMBL9405637 | 0.80 | DRD2 (0.49) | SRCALDH1A1DRD2DRD3HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971878-B1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7256204-B2 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20040077867-A1 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6613805-B2 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6310107-B1 | (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | SIRT1 2994/4885POLA1 1794/4885SRC 2856/4885 |
| US-20040077867-A1 | Amine compounds, their production and use | QSOX1, APP, NPR1 | SIRT1 2167/4885POLA1 1552/4885SRC 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.